Bio-Techne Corporation (NASDAQ: TECH) related to its sale to Merck KGaA. Under the terms of the proposed transaction, Bio-Techne shareholders are expected to receive $73.00 per share in cash.
Bio-Techne Corporation (NASDAQ: TECH) related to its sale to Merck KGaA. Under the terms of the proposed transaction, Bio-Techne shareholders are expected to receive $73.00 per share in cash.